Previous 10 | Next 10 |
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019 financial results on March 16, 2020. Oncternal’s management will hos...
Preliminary results from a Phase 1/2 clinical trial evaluating Oncternal Therapeutics' ( ONCT +4.3% ) lead candidate cirmtuzumab, combined with AbbVie and J&J's Imbruvica (ibrutinib), in blood cancer patients showed encouraging action in a subset of participants with relapsed/refr...
50% (six of twelve) evaluable patients with relapsed/refractory MCL achieved complete responses (CR) in the dose-finding cohort of the ongoing Phase 1/2 clinical trial 83% best objective response rate (ORR) and 100% clinical benefit rate Oncternal Therapeutics, Inc. (Nasdaq: ...
- Anti-ROR1 CAR-T cell therapy demonstrated expansion, persistence and anti-tumor activity in animal model of human leukemia Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced t...
- Four of seven evaluable patients with HER2-negative, metastatic or locally-advanced unresectable breast cancer achieved a partial response for an objective response rate of 57% - Cirmtuzumab in combination with paclitaxel has been well tolerated Oncternal Therapeutics, Inc. (Nas...
Dose-finding cohort demonstrated clinical activity and was generally well-tolerated TK216 has been granted Orphan Drug and Fast Track Designations for treatment of patients with relapsed/refractory Ewing sarcoma Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage b...
The following slide deck was published by Oncternal Therapeutics, Inc. in conjunction with this Read more ...
Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100% Cirmtuzumab has been very well tolerated in this trial Inhibition of ROR1 signaling by cirmtuzumab was shown to reverse gene expression signatur...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical ...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Jaffray 31st ...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...